Two Embarcadero Center Suite 1900, San Francisco, CA USA 94111
Represented appellant Levi Strauss & Co. in successful appeal from the trial court's judgment rejecting its trademark dilution claim. The Ninth Circuit agreed with Levi Strauss that the former "identical or nearly identical" standard for similarity in a dilution by blurring claim did not survive the Trademark Dilution Revision Act of 2006 (TDRA). Levi Strauss & Co. v. Abercrombie & Fitch Trading Co., 633 F.3d 1158 (9th Cir. 2011).
Design and implement various enforcement programs aimed at stopping the distribution of counterfeit and gray market LEVI’S® jeans, as well as policing the unauthorized online distribution of the company’s products and use of its trademarks.
Represented a number of amicus curiae including the National Association of Criminal Defense Lawyers and the ACLU in successful appeal involving indigents’ right to counsel at initial bail hearings. DeWolfe v. Richmond, 2012 Md. LEXIS 1, Md. Court of Appeals No. 34 (Jan. 4, 2012).
Represented appellee San Francisco Women's Motorcycle Contingent in successful effort to affirm the holding of the Trademark Trial and Appeal Board that appellant McDermott did not have standing to challenge the trademark registration issued for the mark DYKES ON BIKES. McDermott v. San Francisco Women's Motorcycle Contingent, 240 Fed. Appx. 865 (Fed. Cir. 2007).
Represented Watson in pending ANDA litigation of generic version of SEASONIQUE®. Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc., et al., No. 3:08-cv-116 (D. Nev. filed Mar. 6, 2008).
Represents Levi Strauss & Co. (Levi) for setting brand enforcement strategies, distribution policies (including gray marketing), anti-counterfeiting efforts and enforcement of trademarks, copyrights and distribution policies in cease and desist efforts and litigation. Hundreds of matters, including over 75 lawsuits, have been handled. We have also advised Levi regarding notice and take-down issues under the DMCA.
Represented appellee Watson Pharmaceuticals, Inc. in successful defense of district court’s order dismissing Bayer’s claims of patent infringement. The Federal Circuit agreed with Watson that for a generic drug maker to infringe a method-of-use patent, the proposed label must indicate that the drug is approved (i.e., safe and effective) for the claimed method. Bayer Schering Pharma AG v. Lupin, Ltd., et al., 2012 U.S. App. LEXIS 7570, Fed. Cir. Appeal No. 2011-1143 (April 16, 2012).
Representing amicus curiae The Financial Services Roundtable in pending appeal involving the proper standard for direct patent infringement when separate actors each perform different steps of a method claim. Akamai Technologies, Inc. et al v. Limelight Networks, Inc., Fed. Cir. Appeal No. 2009-1372 (pending).
Successfully defended follow-on damages patent infringement action against Korean petrochemical concern by defeating claims on summary judgment. (N.D. Ohio).
Stanford University J.D. (1987) Order of the Coif, Stanford Law Review
Yale University B.A. (1980) magna cum laude
U.S. Bankruptcy Court for the Central District of California
U.S. Court of Appeals for the Ninth Circuit
U.S. District Court for the Northern District of California
U.S. District Court for the Southern District of California
U.S. Court of Appeals for the Ninth Circuit - Honorable Stephen Reinhardt
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.